CLAIM CARD
The evidence base for PCSK9 inhibitors and cardiometabolic outcomes draws from a systematic review and meta-analysis, a meta-epidemiological study, and two observational cohorts. Wang 2022, a Bayesian network meta-analysis, examined PCSK9 inhibitors for secondary cardiovascular prevention in adults, finding that alirocumab was associated with reductions in all-cause mortality compared with control (RR 0.83, 95% CrI 0.72–0.95). Evolocumab was associated with reductions in low-density lipoprotein cholesterol, though with some variability across trials. Bruggen 2024 conducted a meta-epidemiological assessment of baseline imbalances in evolocumab and alirocumab trials, reporting that only baseline BMI showed a statistically significant lower pooled mean for the drug versus placebo groups (MD −0.16; 95% CI −0.24 to −0.09; P = 0.03). The two observational cohorts—Liu 2023 and Azizzadeh 2026—focused on vascular aging pathways rather than clinical endpoints.
Evidence grade: exploratory
Contradiction status: none
Publication: 4753c82f-24d3-490c-8a23-6cc8d4194c24
Provenance: Derivation Web chain
Citation Support
source_1Ma 2025source_2Schwartz 2021source_3Lehrke 2024source_4Imran 2023source_5Faraidy 2023